Journal - Research Article

Di Bacco, A., Bahlis, N. J., Munshi, N. C., Avet-Loiseau, H., Masszi, T., Viterbo, L., … Ganly, P., … Moreau, P. (2020). c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. european journal of haematology, 105(1), 35-46. doi: 10.1111/ejh.13405

Hock, B. D., Mulholland, K. S., Ganly, P., McKenzie, J. L., Pearson, J. F., & Macpherson, S. A. (2019). Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre. Internal Medicine Journal, 49, 598-606. doi: 10.1111/imj.14155

Mascarenhas, J., Virtgaym, E., Stal, M., Blacklock, H., Gerds, A. T., Mesa, R., Ganly, P., … Moshier, E. (2018). Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: A sponsor-independent international study. Annals of Hematology, 97(8), 1369-1374. doi: 10.1007/s00277-018-3309-6

Mesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., … Ganly, P., … Harrison, C. N. (2017). Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. Lancet Haematology, 4(5), e225-e236. doi: 10.1016/S2352-3026(17)30027-3

Avet-Loiseau, H., Bahlis, N. J., Chng, W.-J., Masszi, T., Viterbo, L., Pour, L., Ganly, P., … Richardson, P. G. (2017). Ixazomib significantly prolongs progression-free survival in high-rick relapse/refractory myeloma patients. Blood, 130(24), 2610-2618. doi: 10.1182/blood-2017-06-791228

Gerstung, M., Papaemmanuil, E., Martincorena, I., Bullinger, L., Gaidzik, V. I., Paschka, P., … Ganly, P., … Campbell, P. J. (2017). Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nature Genetics, 49, 332-340. doi: 10.1038/ng.3756

Grigg, A., Butcher, B., Khodr, B., Bajel, A., Hertzberg, M., Patil, S., D'Souza, A., Ganly, P., … on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG). (2017). An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: Results of a phase II prospective trial. Bone Marrow Transplantation, 52, 1288-1293. doi: 10.1038/bmt.2017.108

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., … Ganly, P., … Campbell, P. J. (2016). Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine, 374(23), 2209-2221. doi: 10.1056/NEJMoa1516192

Bolli, N., Li, Y., Sathiaseelan, V., Raine, K., Jones, D., Ganly, P., … Munshi, N. C. (2016). A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer Journal, 6(9), e467. doi: 10.1038/bcj.2016.72

Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., … Ganly, P., … for the TOURMALINE-MM1 Study Group. (2016). Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine, 374, 1621-1634. doi: 10.1056/NEJMoa1516282

Mant, S., Taylor, G., Dutton, D., Butler, A., Browett, P., & Ganly, P. (2015). Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic leukemia: A series of six cases. Leukemia & Lymphoma, 56(3), 774-778. doi: 10.3109/10428194.2014.927460

Ganly, P., Cole, S., Trengrove, A., & Butler, A. (2014). Outcomes of allogeneic haematopoietic stem cell transplants at a small New Zealand centre: Does size matter? Internal Medicine Journal, 44(7), 683-689. doi: 10.1111/imj.12456

Fernyhough, L. J., Hock, B. D., Taylor, J., Pearson, J., & Ganly, P. (2013). Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: A retrospective study at a single New Zealand centre. Internal Medicine Journal, 43(2), 130-137. doi: 10.1111/j.1445-5994.2012.02819.x

Nivison-Smith, I., Dodds, A. J., Doocey, R., Ganly, P., Gibson, J., Ma, D. D. F., … Bradstock, K. F. (2011). Allogeneic haemopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: Factors associated with improved survival outcome. Leukemia & Lymphoma, 52(9), 1727-1735. doi: 10.3109/10428194.2011.582201

Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., . . ., Ganly, P. S., & et al (2010). Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 28(10), 1756-1765. doi: 10.1200/JCO.2009.26.4556

Kim, D.-W., Banavali, S. D., Bunworasate, U., Goh, Y.-T., Ganly, P., Huang, H., … Wong, R. (2010). Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy group. Leukemia Research, 34(11), 1459-1471. doi: 10.1016/j.leukres.2010.03.033

Marr, H., McDonald, E.-J., Merriman, E., Smith, M., Mangos, H., Stoddart, C., & Ganly, P. (2009). Successful treatment of transplant-associated microangiopathy with rituximab [Clinical correspondence]. New Zealand Medical Journal, 122(1292). Retrieved from http://journal.nzma.org.nz/journal/122-1292/3534/content.pdf

Hernandez, E., Ganly, P., Charu, V., DiBenedetto, J., Tomita, D., Lillie, T., … ARANESP 20030232 Study Group. (2009). Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Current Medical Research & Opinion, 25(9), 2109-2120. doi: 10.1185/03007990903084164

Ganly, P. S., Keeman, H., Spearing, R. L., Smith, M. P., Patton, N., Merriman, E. G., & Gibbons, S. S. (2008). Written advice can provide a safe and acceptable alternative to new patient assessment for selected referrals to haematologists. Medical Journal of Australia, 188(1), 9-12.

Sanders, J., Pithie, A., Ganly, P., Surgenor, L., Wilson, R., Merriman, E., … Chambers, S. (2008). A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. Journal of Antimicrobial Chemotherapy, 62(4), 809-815. doi: 10.1093/jac/dkn284

Ganly, P., Hanrahan, V., Baker, B., & Romeril, K. (2007). Identification of JAK2^V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera. American Journal of Hematology, 82, 80-82.

Ganly, P., & Spearing, R. (2006). Treatment with intravenous immunoglobulin is not a panacea but should be limited to those who can benefit [Editorial]. New Zealand Medical Journal, 119(1246). Retrieved from http://journal.nzma.org.nz/journal/119-1246/2335/content.pdf

Gough, S. M., Benjes, S. M., McDonald, M., Heaton, D., Ganly, P., & Morris, C. M. (2006). Translocation (5;10)(q22;q24) in a case of acute lymphoblastic leukemia. Cancer Genetics & Cytogenetics, 165, 36-40. doi: 10.1016/j.cancergencyto.2005.08.008

Chambers, S. T., Sanders, J., Patton, W. N., Ganly, P., Birch, M., Crump, J. A., & Spearing, R. L. (2005). Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: Results from a prospective randomized controlled trial. Journal of Hospital Infection, 61, 53-61.

Ganly, P., McDonald, M., Spearing, R., & Morris, C. M. (2004). Constitutional t(5;7)(q11;p15) rearranged to acquire monosomy 7q and trisomy 1q in a patient with myelodysplastic syndrome transforming to acute myelocytic leukemia. Cancer Genetics & Cytogenetics, 149(2), 125-130.

Ganly, P. S., Walker, L. C., & Morris, C. M. (2004). Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia. Leukemia & Lymphoma, 45(1), 1-10.

Carradice, D., Austin, N., Bayston, K., & Ganly, P. S. (2002). Successful treatment of acute promyelocytic leukaemia during pregnancy. Clinical & Laboratory Haematology, 24, 307-311.

Walker, L. C., Campbell, H. J., Corbett, R., Spearing, R. L., Heaton, D. C., Macdonald, D. H., Morris, C. M., & Ganly, P. S. (2002). A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia. British Journal of Haematology, 117(4), 878-881. doi: 10.1046/j.1365-2141.2002.03512.x

Mullin, J. L., Brennan, S., Ganly, P. S., & George, P. M. (2002). Fibrinogen Hillsborough: A Novel γ309Gly→ Asp Dysfibrinogen. Blood, 99, 3597-3610.

Jackson, G., Taylor, P., Smith, G. M., Marcus, R., Smith, A., Chu, P., … Ganly, P. S., … Wilson, M. P. (2001). A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine abd granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. British Journal of Haematology, 112(1), , 127-137. doi: 10.1046/j.1365-2141.2001.02551.x

Ganly, P. S., & Beard, M. (2001). Osteoclasts in Paget's disease of bone. British Journal of Haematology, 113, 259.

Whittle, A. T., Davis, M., Shovlin, C. L., Ganly, P. S., Haslett, C., & Greening, A. P. (2001). Alveolar macrophage activity and the pulmonary complications of haematopoietic stem cell transplantation. Thorax, 56, 941-946.

^ Top of page

Journal - Research Other

Ganly, P., Downing, J., Stiven, P., Frizelle, F., & Badami, K. (2011). Clinical and serological diagnoses of a patient with vancomycin-induced thrombocytopenia [Letter to the editor]. Transfusion Medicine, 21(2), 137-139. doi: 10.1111/j.1365-3148.2010.01052.x

Ganly, P., Saleem, M., Marr, H., Burt, M., Florkowski, C., & Williamson, A. (2008). Not walking or communicating: Is all well? [Case report]. Lancet, 372(9655), 2086. doi: 10.1016/S0140-6736(08)61870-X